In additional studies in PTCL and MF, one-third to two-third of patients responded when CD30 + expression was < 10%, including some who had no CD30 expression [10]. This evidence concerns the gene TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma.